Abstract
People living with HIV (PLWHIV) in Germany are facing new challenges in an aging society. The number of patients with multiple comedications is growing significantly.The US-American HIV-guidelines (DHHS) recommend treating PLWHIV in a multidisciplinary team, including pharmacist. This concept has not been implemented in Germany. 12-month prospective randomized case-control study to evaluate the influence of implementing a pharmacist to an interdisciplinary HIV-care provider team. The role of the pharmacist included assesing comedications and dietary supplements and optimizing the daily medication schedule. Main endpoints changes in imunologic markers such as CD4-cell count and the number of dietary supplements and their influence on the antiretroviral therapy. 37 Patients were recruted for the study. 19 Patients received intervention by the pharmacist, 18 patients were randomized to the control group, which did not receive intervention by the pharmacist. Mean number of comedications in both groups was 5. In 10,5% of the patients in the intervention group use of dietary supplements was detected, which were contraindicated in combination with ART. Immunologic markers showed a tendency to improve in the intervention group after 6 month, but this difference could not be detected significantly. Table 1 Baseline characteristicsTabled 1Variable by pharmacist (Baseline)without intervention by pharmacist (Baseline)w/intervention by pharmacist (Baseline)without intervention by pharmacist (6 month after initiation)w/intervention by by pharmacist (6 month after initiation)(n = 18)(n = 19)(n = 18)(n = 19)Age (years; mean ± SD)46 ± 8.548 ± 10-- range (years)35 – 7938– 84--Sex (% male/ female)83.3/16.773.7/26.3--Number of comedication (mean ± SD )5 ± 2.55 ± 2.5--CD4 /µl (mean ± SD)589 ± 307528 ± 171563 ± 320515 ± 172CD4 % (mean ± SD)27.6 ± 9.626.9 ± 9.627.4 ± 9.329.5 ± 8.1CD4 / CD8 Ratio (mean ± SD)0.74 ± 0.120.74 ± 0.090.71 ± 0.070.77 ± 0.08 Open table in a new tab Our data indicates, that a pharmacist should be a permanent member of every HIV-care provider team. Final results of the outcome of the imunologic markers will be reported after study closure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
